Adial Pharmaceuticals Inc (NASDAQ: ADIL) received a Buy rating and a $5 price target from Maxim Group analyst Jason McCarthy today. The company’s shares closed yesterday at $1.88, close to its 52-week low of $1.85.
McCarthy noted:
“We are initiating coverage of $5 price target. Adial is developing AD04, an ultra-low-dose ondansetron therapy (targeting 5′-HT3) for the treatment of alcohol use disorder (AUD).”
According to TipRanks.com, McCarthy is a 4-star analyst with an average return of 3.5% and a 39.2% success rate. McCarthy covers the Healthcare sector, focusing on stocks such as SELLAS Life Sciences Group Inc, ContraVir Pharmaceuticals Inc, and Sonoma Pharmaceuticals Inc.
Adial Pharmaceuticals Inc has an analyst consensus of Moderate Buy, with a price target consensus of $5.
See today’s analyst top recommended stocks >>
The company has a one-year high of $4.40 and a one-year low of $1.85. Currently, Adial Pharmaceuticals Inc has an average volume of 19.12K.
Based on the recent corporate insider activity of 8 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of ADIL in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
